Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2389]
News [5185]
Articles [212]
Editorials [8]
Conferences [138]
elearning [14]
GLP-1 receptor agonists improve lung cancer outcomes
GLP-1 receptor agonists improve lung cancer outcomes
WCLC 2025: Ifinatamab deruxtecan demonstrates high response rate in previously treated extensive-stage small cell lung cancer: Phase 2 IDeate-Lung01 trial
WCLC 2025: Ifinatamab deruxtecan demonstrates high response rate in previously treated extensive-stage small cell...
WCLC 2025: Phase III trial finds hypofractionated radiotherapy with chemotherapy offers comparable survival and lower toxicity to conventional schedule in LS-SCLC
WCLC 2025: Phase III trial finds hypofractionated radiotherapy with chemotherapy offers comparable survival and...
WCLC 2025: Aumolertinib plus chemotherapy improves progression-free survival in NSCLC with EGFR and concomitant tumor suppressor genes: ACROSS 2 phase III study
WCLC 2025: Aumolertinib plus chemotherapy improves progression-free survival in NSCLC with EGFR and concomitant...
WCLC 2025: FLAURA2 trial shows osimertinib plus chemotherapy improves overall survival in eGFR-mutated advanced NSCLC
WCLC 2025: FLAURA2 trial shows osimertinib plus chemotherapy improves overall survival in eGFR-mutated advanced...
WCLC 2025: Crizotinib fails to improve disease-free survival in resected early-stage ALK+ NSCLC
WCLC 2025: Crizotinib fails to improve disease-free survival in resected early-stage ALK+ NSCLC
WCLC 2025: Ivonescimab plus chemotherapy improves progression-free survival in patients with EGFR+ NSCLC following 3rd-generation EGFR-TKI therapy
WCLC 2025: Ivonescimab plus chemotherapy improves progression-free survival in patients with EGFR+ NSCLC following...
WCLC 2025: Zidesamtinib shows durable responses in ROS1 TKI pre-treated NSCLC, including patients with CNS disease and ROS1 G2032R mutations
WCLC 2025: Zidesamtinib shows durable responses in ROS1 TKI pre-treated NSCLC, including patients with CNS disease...
WCLC 2025: New antibody-drug conjugate shows promising efficacy in EGFR-mutated NSCLC patients
WCLC 2025: New antibody-drug conjugate shows promising efficacy in EGFR-mutated NSCLC patients
Viral mechanism behind nasopharyngeal cancer spread, opening new avenues for targeted treatments
Viral mechanism behind nasopharyngeal cancer spread, opening new avenues for targeted treatments

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation